BiotechTube

Ifinatamab deruxtecan (I-DXd)

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumor

Conditions

Advanced Solid Tumor, Malignant Solid Tumor

Trial Timeline

Nov 3, 2019 → Oct 31, 2029

NCT ID
NCT04145622

About Ifinatamab deruxtecan (I-DXd)

Ifinatamab deruxtecan (I-DXd) is a phase 1/2 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04145622. Target conditions include Advanced Solid Tumor, Malignant Solid Tumor.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Solid Tumor were approved

Approved (16) Terminated (1) Active (4)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅letrozoleJiangsu Hengrui MedicineApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅FulvestrantAstraZenecaApproved
✅Zoladex and CasodexAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05280470Phase 2Active
NCT04145622Phase 1/2Recruiting

Competing Products

20 competing products in Advanced Solid Tumor

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21